microRNA Biomarkers as Potential Diagnostic Markers for Cancer - Genomic Biomarkers for Pharmaceutical Development - page 121

[159] Xie L, Chen X, Wang L, Qian X, Wang T, Wei J, et al. Cell-free miRNAs may indicate diagnosis and docetaxel
sensitivity of tumor cells in malignant effusions. BMC Cancer 2010;10:591.
[160] Wei J, Gao W, Zhu CJ, Liu YQ, Mei Z, Cheng T, et al. Identiication of plasma microRNA-21 as a biomarker
for early detection and chemosensitivity of non-small cell lung cancer. Chin J Cancer 2011;30:407-14.
[161] Silva J, Garcia V, Zaballos A, Provencio M, Lombardia L, Almonacid L, et al. Vesicle-related microRNAs in
plasma of nonsmall cell lung cancer patients and correlation with survival. Eur Respir J 2011;37:617-23.
[162] Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin 2009;59:225-49.
[163] Weir HK, Thun MJ, Hankey BF, Ries LA, Howe HL, Wingo PA, et al. Annual report to the nation on the status
of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer
Inst 2003;95:1276-99.
[164] Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin 2007;57:43-66.
[165] Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical
Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol
2007;25:5287-312.
[166] Schrauder MG, Strick R, Schulz-Wendtland R, Strissel PL, Kahmann L, Loehberg CR, et al. Circulating micro-
RNAs as potential blood-based markers for early stage breast cancer detection. PLoS One 2012;7:e29770.
[167] Zhao R, Wu J, Jia W, Gong C, Yu F, Ren Z, et al. Plasma miR-221 as a predictive biomarker for chemore-
sistance in breast cancer patients who previously received neoadjuvant chemotherapy. Onkologie
2011;34:675-80.
[168] Schwarzenbach H, Milde-Langosch K, Steinbach B, Muller V, Pantel K. Diagnostic potential of PTEN-
targeting miR-214 in the blood of breast cancer patients. Breast Cancer Res Treat 2012;134:933-41.
[169] Xiong X, Ren HZ, Li MH, Mei JH, Wen JF, Zheng CL. Down-regulated miRNA-214 induces a cell cycle G1
arrest in gastric cancer cells by up-regulating the PTEN protein. Pathol Oncol Res 2011;17:931-7.
[170] van Schooneveld E, Wouters MC, Van der Auwera I, Peeters DJ, Wildiers H, Van Dam PA, et al. Expression
proiling of cancerous and normal breast tissues identiies microRNAs that are differentially expressed in
serum from patients with (metastatic) breast cancer and healthy volunteers. Breast Cancer Res 2012;14:R34.
[171] Jung EJ, Santarpia L, Kim J, Esteva FJ, Moretti E, Buzdar AU, et al. Plasma microRNA 210 levels correlate
with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer 2012;118:2603-14.
[172] Wu X, Somlo G, Yu Y, Palomares MR, Li AX, Zhou W, et al. De novo sequencing of circulating miRNAs iden-
tiies novel markers predicting clinical outcome of locally advanced breast cancer. J Transl Med 2012;10:42.
[173] Wang H, Tan G, Dong L, Cheng L, Li K, Wang Z, et al. Circulating MiR-125b as a marker predicting chemore-
sistance in breast cancer. PLoS One 2012;7:e34210.
[174] Cuk K, Zucknick M, Heil J, Madhavan D, Schott S, Turchinovich A, et al. Circulating microRNAs in plasma
as early detection markers for breast cancer. Int J Cancer 2013;132(7):1602-12.
[175] Madhavan D, Zucknick M, Wallwiener M, Cuk K, Modugno C, Scharpff M, et al. Circulating microRNAs as
surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. Clin Cancer
Res 2012;18(21):5972-82.
[176] Si H, Sun X, Chen Y, Cao Y, Chen S, Wang H, et al. Circulating microRNA-92a and microRNA-21 as novel
minimally invasive biomarkers for primary breast cancer. J Cancer Res Clin Oncol 2012;139(2):223-9.
[177] Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
[178] Song JH, Meltzer SJ. MicroRNAs in pathogenesis, diagnosis, and treatment of gastroesophageal cancers.
Gastroenterology 2012;143:35-47, e2.
[179] Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S, et al. Relation between microRNA expres-
sion and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol
2010;11:136-46.
[180] Valladares-Ayerbes M, Reboredo M, Medina-Villaamil V, Iglesias-Diaz P, Lorenzo-Patino MJ, Haz M, et al.
Circulating miR-200c as a diagnostic and prognostic biomarker for gastric cancer. J Transl Med 2012;10:186.
[181] Tsai KW, Liao YL, Wu CW, Hu LY, Li SC, Chan WC, et al. Aberrant expression of miR-196a in gastric cancers
and correlation with recurrence. Genes Chromosomes Cancer 2012;51:394-401.
[182] Wang M, Gu H, Wang S, Qian H, Zhu W, Zhang L, et al. Circulating miR-17-5p and miR-20a: molecular
markers for gastric cancer. Mol Med Report 2012;5:1514-20.
[183] Liu H, Zhu L, Liu B, Yang L, Meng X, Zhang W, et al. Genome-wide microRNA proiles identify miR-378 as a
serum biomarker for early detection of gastric cancer. Cancer Lett 2012;316:196-203.